Last reviewed · How we verify

NCT04117321

Mother-infant Microbiota Transmission and Its Link to the Health of the Baby

Recruiting now Last updated 29 May 2024
What this trial tests

trial in Gut Microbiome in 20,000 participants. Currently enrolling.

Timeline
23 September 2019
Primary endpoint
2 October 2026
2 October 2027

Quick facts

Lead sponsorChinese University of Hong Kong
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment20,000
Start date23 September 2019
Primary completion2 October 2026
Estimated completion2 October 2027
Sites1 location across China

Conditions studied

Sponsor

Chinese University of Hong Kong

Who can join

Eligibility, any sex, with Gut Microbiome or Mother to Child Transmission. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The human intestinal tract harbors a diverse and complex microbial community, known as gut microbiota, which is critical in sustaining physiology, metabolism, nutrition and immune function. Dysbiosis of gut microbiota has been linked with obesity, hyperglycemia, hyperlipidemia, inflammatory bowel disease and other chronic inflammatory diseases. Gut microbiota is affected by host genetic markup, diet and life style; and therefore varied by human races and geographical locations. The development of gut microbiota starts before birth. The infant's microbiome can impact on human health in later life. The microbiome of pregnant women are associated with early-life microbiota of their offspring as well as growth, neurodevelopment and the development of allergic and neurocognitive disorders. Early childhood, when the microbiota is less mature and more malleable, is a golden age for microbiota manipulation to prevent disease. Studying microbiota at this golden age also allow us to dissect the development of a faulty microbiota and identify therapeutic targets to reverse it and cure diseases that are already developed.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. MOMMY study profile: An integrative early-life multi-omics cohort in China.
    Zhang L, Liu Y, Wang S, Ching JY, et al · · 2025 · PMID 41676450 · DOI 10.1002/imo2.70068

Verify or expand the search:

Other recruiting trials for Gut Microbiome

Currently open trials in the same condition.

Other Chinese University of Hong Kong trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04117321.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing